



INFECTIOUS DISEASES

Infectious Disease Trials: the Julius Clinical Solution

Julius Clinical manages global clinical drug trials that will have a major impact on medicine and make a real difference to people's lives around the world.

Our unique combination of scientific leadership and operational excellence ensures that the trial data is of the highest quality. Our internationally recognised academic leaders are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and credibility combined with operational excellence means that we are uniquely equipped to assist in providing answers for today's clinical drug development challenges.

Infectious Diseases are a significant burden on public health and economic stability of societies all over the world. The threat posed by infectious diseases is deepened by the continued emergence of new, unrecognised pathogens and the re-emergence of old infectious diseases, creating a never-ending cycle. While the emergence of novel treatments will generate new opportunities, important challenges in clinical trials remain – from managing overall costs to maintaining strict operational oversight. There is also the challenge of patient recruitment – diagnosis of a disease often takes several days, but patients must be enrolled in a study within 24 hours, and some diseases are seasonally active, appearing and disappearing quickly.

INFECTIOUS DISEASES

The Challenges:

- Difficulty in finding appropriate patients due to large number of competing trials by many companies
- Large study size – 31% of Phase III trials need 1000+ patients
- Lengthy trials result in challenges for patient recruitment and retention
- KOL / KOI needed to provide expert knowledge for defining actual endpoints – identification of the right lead investigator

Our Solution:

- Global Scientific Networks – ReSViNET, AfricaNET – enable access to more patients
- Our multi-country Primary Care Research Network aids in patient recruitment and retention
- Peer-to-peer Leadership model helps stimulate recruitment and share best practices
- Our in-house Scientific Officers have extensive knowledge of current infectious disease treatment and trial methodology

TRACK RECORD (a selection) | INFECTIOUS DISEASES

STUDY	PERIOD	PATIENTS	THERAPEUTIC AREA
Anti-viral in children	Ongoing	Ongoing	RSV in children
Immuno-globulin in pre-term babies	Ongoing	Ongoing	RSV in pre-term babies
CAPiTA	2008 - 2013	85,000	Pneumococcal vaccination
CAP-PILOT	2008 - 2009	1,200	Pneumococcal vaccination
MINOES	2005 - 2008	1,005	Pneumococcal vaccination
EPIFLU	2005 - 2007	735	Influenza vaccination
CIRA	2000 - 2007	390	Hepatitis C
PRIMAKID	2003 - 2005	579	Respiratory Tract Infection in children



Louis Bont, MD, PhD, is Paediatric Infectious Diseases Specialist and Leader of the RSV Research Group at the University Medical Center Utrecht in Utrecht, The Netherlands. Prof. Bont is also one of our Associated Scientists.



Broederplein 41-43
3703 CD Zeist
The Netherlands

+31 (0)30 656 99 00
info@juliusclinical.com
www.juliusclinical.com